Barrett’s Esophagus Care: Reflux Control, Surveillance and Ablation When Dysplasia Appears

The letter arrives a week after a routine endoscopy that was supposed to explain a decade of heartburn. Two words are circled: intestinal metaplasia. Below them, in smaller print, three more: no dysplasia. By midnight the search history reads like a spiral, and the phrase that keeps surfacing is precancerous.

That word does a lot of unearned frightening. Barrett’s esophagus treatment is, for most people, a program of watchfulness rather than intervention: acid control, a repeat scope every few years, and a clear plan for what happens if the cells ever start to look disordered. Ablation, the part everyone reads about first, is reserved for a minority.

This explainer walks through what the changed lining actually is, how it is graded, why surveillance intervals are set the way they are, what radiofrequency ablation involves when dysplasia does appear, and which questions are worth asking the gastroenterologist who has seen your biopsies.

What actually happens in Barrett's esophagus?

Swallow, and food travels down a muscular tube roughly ten inches long whose lining is built like the inside of your cheek: flat, layered squamous cells designed for friction, not acid. The stomach below is lined very differently, with tall columnar cells that pump out protective mucus. A ring of muscle, the lower esophageal sphincter, is meant to keep the two worlds apart.

When that valve leaks for years, acid and bile wash repeatedly over the bottom of the esophagus. The tissue responds the only way it can. Flat squamous cells are gradually replaced by columnar, intestine-like cells that tolerate acid better. Pathologists call this intestinal metaplasia, a term that simply means one mature cell type has swapped itself for another. That swap is Barrett’s esophagus.

The trade has a catch. The new lining copes with reflux, but its cells divide in a chemically hostile environment and accumulate genetic errors more readily than the original tissue. Over years, some of those errors can produce dysplasia, cells that look disordered under the microscope, and rarely, esophageal adenocarcinoma. Barrett’s is therefore described as a precancerous change, though most people who have it never develop cancer, a point the Mayo Clinic makes plainly.

Barrett’s itself produces no symptoms. Any heartburn, regurgitation or sour taste comes from the reflux that caused it, not from the changed lining, and a meaningful share of people diagnosed have never had bothersome heartburn at all. The people most likely to develop it share a recognizable profile: long-standing gastroesophageal reflux disease, male sex, age over 50, white ethnicity, weight carried around the waist, a smoking history and a family history of Barrett’s or esophageal cancer. Estimates cited by the National Institute of Diabetes and Digestive and Kidney Diseases put its frequency at roughly 2 to 7 percent of adults, most of them undiagnosed.

How is Barrett's esophagus diagnosed and graded?

There is no blood test and no scan for Barrett’s esophagus. The diagnosis is made by looking and then sampling. An upper endoscopy, in which a thin flexible tube with a camera is passed through the mouth while you are sedated, lets the gastroenterologist see salmon-pink, velvety patches of columnar lining creeping up above the stomach junction, where normal lining is pale and glossy.

Seeing is not enough. Small biopsies, pinches of tissue a few millimeters across, are taken in a systematic pattern along the affected segment so that patchy abnormalities are not missed. A pathologist confirms intestinal metaplasia and assigns a grade. Those grades are the language your whole care plan will be written in:

• No dysplasia: Barrett’s lining is present but the cells look orderly.
• Indefinite for dysplasia: inflammation or other changes make the sample too hard to call either way.
• Low-grade dysplasia: cells show mild but genuine disorder in shape and arrangement.
• High-grade dysplasia: marked disorder, the last step before invasion; the cells have not breached the surface layer.
• Intramucosal adenocarcinoma: cancer confined to the innermost layer, still often treatable through the endoscope.

Because distinguishing low-grade dysplasia from harmless inflammation is genuinely difficult, guidelines ask that any dysplasia be confirmed by a second pathologist with gastrointestinal expertise before treatment decisions are made. The Mayo Clinic describes this double-reading as routine.

Two more measurements matter. The length of the abnormal segment is recorded, with segments of 3 centimeters or more described as long-segment and shorter ones as short-segment, according to the Cleveland Clinic. Longer segments carry a higher risk of progression. The endoscopist also documents whether the columnar lining circles the whole esophagus or runs up in tongues, using a standardized scoring system so that future scopes can be compared like for like.

Barrett's esophagus treatment: the three-part plan

Ask what Barrett’s esophagus treatment involves and the answer sounds almost anticlimactic for a condition with the word precancerous attached: control the reflux, keep watching, and act on the lining only when the cells start misbehaving. That restraint is deliberate and evidence-based.

The first part is reflux control. Acid suppression does not make Barrett’s disappear, but ongoing acid exposure fuels the inflammation in which dysplasia develops, and healing the surface makes the pathologist’s job easier. The second part is surveillance, scheduled endoscopies with biopsies at intervals set by the last grade. The third is endoscopic eradication therapy, a family of techniques that remove or destroy the abnormal lining so normal squamous cells can regrow, reserved for confirmed dysplasia or very early cancer.

Why not simply burn away every patch of Barrett’s the day it is found? Because the numbers do not favor it. For a lining that shows no dysplasia, the yearly chance of cancer is well under 1 percent according to the NIDDK, while ablation carries small but real risks of narrowing, bleeding and perforation, requires several sessions, and does not end the need for surveillance. Treating everyone would expose many people to procedures to prevent a handful of cancers. Treating those with confirmed high-grade dysplasia, where progression is far more likely, shifts that balance decisively.

My own view, shaped by what the evidence keeps showing, is that the single most valuable act in Barrett’s care is unglamorous: turning up for the scheduled endoscopy. Cancers found through surveillance tend to be caught at an early, endoscopically treatable stage. Cancers found because someone waited until food started sticking are a different disease. Which part of the plan applies to you, and when, is a decision for the gastroenterologist who has seen your biopsies.

Reflux control: what acid suppression does and doesn't do

Most people with Barrett’s esophagus are advised to take a proton pump inhibitor, a class of medicine that switches off the acid-producing pumps in the stomach’s lining cells. Because the pumps are blocked rather than the acid neutralized, the effect builds over several days and lasts as long as the medicine is taken. Histamine-2 blockers, an older class that dampens one of the signals telling those cells to make acid, work faster but less completely and are sometimes used alongside or instead of PPIs at a clinician’s discretion.

What acid suppression can do is heal erosive inflammation, relieve heartburn and reduce the acid bath the Barrett’s lining sits in. What it cannot do is convert columnar cells back to squamous ones. Observational studies have associated regular PPI use with lower rates of progression to dysplasia and cancer, but randomized evidence is limited and the effect, if real, is modest. Guideline bodies recommend PPIs for symptom control and healing, not as a stand-alone cancer prevention strategy, and they do not recommend escalating beyond what controls symptoms unless a specialist has a specific reason.

Aspirin and related anti-inflammatory drugs have been studied for chemoprevention in Barrett’s with mixed results. They are not recommended for that purpose outside an individual clinical assessment, since they carry bleeding risks of their own.

Anti-reflux surgery, most commonly fundoplication, in which the top of the stomach is wrapped around the lower esophagus to reinforce the valve, is an option for people whose reflux is not controlled by medicine or who cannot tolerate it. The Mayo Clinic is careful to note that surgery has not been shown to reverse Barrett’s or to eliminate the need for surveillance. Stopping, switching or intensifying any of these medicines is a conversation with the prescriber, never a solo decision; rebound acid after abrupt withdrawal is uncomfortable and unhelpful for a healing lining.

Barrett's esophagus surveillance endoscopy: how often, and why it matters

Surveillance means repeating the endoscopy and biopsies at planned intervals so that dysplasia is found while it is still confined to the surface. The schedule is anchored to the most recent grade, and the ranges below reflect guidance summarized by the Mayo Clinic and the NIDDK:

• No dysplasia on consecutive endoscopies: repeat roughly every 3 to 5 years, with longer segments often placed toward the shorter end of that range.
• Indefinite for dysplasia: optimize acid suppression and repeat after a few months, so inflammation clears and the cells can be read properly.
• Low-grade dysplasia, confirmed: either repeat in 6 to 12 months or proceed to ablation, a genuine shared decision.
• High-grade dysplasia, confirmed: endoscopic therapy rather than continued watching.

Quality matters as much as timing. A good surveillance scope uses high-definition imaging, takes time to inspect the segment after clearing mucus, targets any visible bump or irregularity first, and then samples the rest in a fixed pattern. Some units add dyes or specialized light settings to make subtle areas stand out. Ask, without embarrassment, whether your biopsies followed a set protocol.

The honest limitation is that surveillance has never been tested in a large randomized trial against no surveillance. The case for it rests on observational data showing that cancers found during scheduled scopes are earlier and more often treatable through the endoscope. That is a reasonable basis for practice, not a guarantee.

Surveillance may also be stopped, by agreement, in people whose other health problems mean a slow-growing lesion is unlikely to affect their life and in whom repeated sedation carries its own hazards. That is a judgment for the treating team and the patient together rather than a rule, and it should be an explicit conversation rather than an appointment that quietly falls off the calendar.

How fast does Barrett's esophagus progress to cancer?

Slowly, for most people, and not at all for the majority. The figure that matters is the annual rate of progression to esophageal adenocarcinoma in Barrett’s without dysplasia, which the NIDDK places at about 0.5 percent per year or lower; more recent large registry studies have tended to land beneath that. Put another way, if 200 people with non-dysplastic Barrett’s were followed for a year, roughly one, or fewer, would be diagnosed with cancer.

Those odds shift as the grade changes. Low-grade dysplasia confirmed by expert pathologists carries a noticeably higher yearly risk, which is why it opens the door to ablation. High-grade dysplasia is a different situation altogether: a substantial fraction of people with it either already harbor an undetected early cancer or progress within a few years, and guidelines treat it as an indication for endoscopic therapy rather than watchful waiting.

Several features nudge the risk upward within any grade: a long segment, male sex, older age, continued smoking, central obesity and a first-degree relative with Barrett’s or esophageal cancer. Others do not change the underlying biology but change how quickly a problem is noticed, chiefly whether surveillance is actually happening.

The question that follows, what all this means for life expectancy, deserves a plain answer. Studies following people with Barrett’s over many years have consistently found that most die of causes unrelated to the esophagus, heart disease chief among them, and that overall survival is similar to or only slightly below that of comparable people without the condition. Barrett’s is a reason to stay engaged with care and to address the heart-health habits that overlap with reflux habits: weight, smoking, alcohol, movement. It is not, on the evidence, a shortened life sentence, and it is worth saying so to the person lying awake with the pathology report.

Radiofrequency ablation for Barrett's esophagus: what the procedure involves

Radiofrequency ablation, RFA, uses controlled heat delivered through the endoscope to destroy the Barrett’s lining to a very shallow depth, sparing the deeper layers so that the esophagus heals with normal squamous tissue rather than scar. It is the most widely used ablation technique and the one with the longest track record.

The procedure is done as an outpatient under sedation, much like a surveillance scope. Before any ablation, the endoscopist inspects the segment for visible nodules. Anything raised is removed first by endoscopic mucosal resection, EMR, in which the abnormal area is lifted with an injection of fluid and snared off. A nodule may contain deeper disease that heat alone would miss, and the removed tissue gives the pathologist a full specimen to stage. Ablation then follows, sometimes at the same session and sometimes weeks later.

For a segment that circles the esophagus, a balloon carrying a fine electrode array is inflated to touch the whole circumference and energy is delivered in brief pulses. For smaller tongues or residual islands, a focal device mounted on the endoscope tip treats specific spots. The coagulated tissue is scraped away and the area treated once more. From the patient’s side, the whole thing is a nap.

Cryotherapy is the main alternative, freezing the lining with liquid nitrogen or carbon dioxide instead of heating it; it is often used when RFA is poorly tolerated or has left stubborn areas. Argon plasma coagulation, a more targeted heat method, is sometimes used for small remnants. Photodynamic therapy, in which a light-sensitizing drug is activated by laser, was an earlier approach that has largely given way to RFA because of its higher rate of strictures and prolonged skin sensitivity to light. Which tool is used, and in what order, depends on the anatomy in front of the endoscopist.

Comparing Barrett's esophagus treatment options side by side

The options in Barrett’s esophagus treatment are not rivals so much as rungs. Each is chosen for a particular grade, a particular anatomy and a particular person. The table is a map of the territory, not a menu; the treating team decides which rung fits.

Approach	What it involves	Usually considered when	Main trade-offs
Reflux control (PPI class, lifestyle, sometimes anti-reflux surgery)	Reduces acid exposure and heals inflammation	Everyone with Barrett’s, at every grade	Does not reverse Barrett’s or remove the need for surveillance
Surveillance endoscopy	Scheduled scopes with systematic biopsies	No dysplasia; indefinite; some confirmed low-grade dysplasia	Repeated sedated procedures; small chance of missed lesions
Endoscopic mucosal resection (EMR)	Lifts and removes a visible nodule	Any raised or irregular area, before ablation	Bleeding, rare perforation; provides tissue for accurate staging
Radiofrequency ablation	Heat destroys flat Barrett’s lining	Confirmed high-grade dysplasia; confirmed low-grade dysplasia by shared decision; after EMR of early cancer	Chest discomfort for days, stricture in a minority, several sessions, recurrence possible
Cryotherapy / argon plasma coagulation	Freezing or targeted heat	Residual areas after RFA, or when RFA is poorly tolerated	Less long-term data than RFA; similar risk profile
Esophagectomy	Surgical removal of part of the esophagus	Cancer that has grown beyond the reach of endoscopic therapy	Major operation with significant recovery and lasting changes to eating

Two patterns are worth drawing out. First, reflux control and surveillance are never replaced by the procedures beneath them; ablation adds to the plan rather than substituting for it, and everyone treated returns to a surveillance schedule afterward. Second, the shift from watching to acting hinges almost entirely on one word from the pathologist, confirmed, which is why the second expert opinion on any dysplasia is not bureaucratic caution but the pivot of the whole strategy.

Who is usually offered ablation, and who is usually asked to wait?

Endoscopic therapy is usually offered to three groups. People with high-grade dysplasia confirmed by a second gastrointestinal pathologist are the clearest candidates, because the near-term risk of cancer is high enough that removing the lining is generally preferred over another round of biopsies. People with an early adenocarcinoma confined to the innermost layer, without features suggesting spread, are often treated by EMR of the lesion followed by ablation of the remaining Barrett’s, avoiding major surgery. And people with confirmed low-grade dysplasia may be offered ablation or intensified surveillance, with guidelines framing this as a choice to be made together after weighing how the person feels about procedures versus uncertainty.

A larger group is asked to wait, and the waiting is not neglect. Barrett’s without dysplasia is not treated by ablation in current guidelines: the yearly cancer risk is too low for the procedure’s risks to pay off, and ablation would not free anyone from surveillance anyway. A biopsy read as indefinite for dysplasia usually means inflammation is muddying the picture, so the plan is to strengthen acid suppression and look again once the surface has healed. Active esophagitis, visible erosion, is treated first for the same reason. Low-grade dysplasia seen on a single biopsy that a second pathologist downgrades goes back to routine surveillance.

Some people are candidates for stopping surveillance altogether, typically those with serious other illnesses or advanced age in whom a slow-growing lesion is very unlikely to change the course of their life. That is a deliberate, documented conversation.

Ablation also has practical prerequisites: a segment that can be fully treated, an esophagus without a tight stricture blocking the devices, and a person able to continue acid suppression through the healing period. Where these are not met, the team may sequence things differently or lean toward cryotherapy.

What the days and weeks after ablation usually look like

Nobody warns you that the first thing you will feel after ablation is often a very ordinary sore throat. The endoscope, the sedation and the treated lining together produce a scratchy throat and a dull ache or burning behind the breastbone that the Mayo Clinic lists among the expected after-effects. For most people this peaks in the first day or two and eases over about a week, managed with the pain relief and acid suppression the team prescribes.

Swallowing can feel tender or slightly sticky as the treated surface sloughs and regrows. Soft, cool foods go down more easily than crusty bread or dry meat, and small sips are kinder than large gulps. A brief period of soft diet is commonly advised, its length set by the endoscopist. Acid suppression is continued and often intensified during healing because a raw surface heals into normal squamous lining far better in a low-acid environment.

Healing takes several weeks, and the new lining needs to mature before it can be judged. Follow-up therefore comes in cycles: a repeat endoscopy some months after each session to check what has regrown and to treat any remaining islands, until no visible or biopsy-proven Barrett’s remains. The NIDDK notes that more than one session is commonly needed; the number depends on segment length and how the tissue responds.

Complications, in neutral terms: bleeding, usually minor; stricture, a narrowing from scar tissue that can make food stick weeks later and is treated by stretching with a dilator during an endoscopy; and perforation, a tear in the wall, which is rare but serious. Once the lining is clear, surveillance resumes, initially more frequently and then at lengthening intervals, because Barrett’s can recur, sometimes hidden beneath the new surface. Ablation is a chapter in the care plan, not its final page.

What should you not do with Barrett's esophagus? Diet, sleep and habits

People ask what they must stop doing, expecting a long list of forbidden foods. The evidence supports a shorter, sterner list. Smoking has the clearest link to progression from Barrett’s to cancer, and stopping is the single lifestyle change most worth the effort. Central weight gain raises abdominal pressure and drives reflux; even modest weight loss tends to ease symptoms. Large late meals, alcohol in quantity and lying down soon after eating all invite acid back up the tube while you are horizontal and swallowing less.

Sleep deserves its own paragraph because nighttime reflux is prolonged reflux. Raising the head of the bed by 6 to 8 inches with blocks under the legs or a wedge under the mattress, a measure the Mayo Clinic recommends, uses gravity to keep stomach contents down; stacking pillows does not work because it bends the neck rather than tilting the torso. Lying on the left side positions the stomach below the esophageal junction and, in reflux studies, produces fewer nighttime acid episodes than the right. Finishing dinner about three hours before bed gives the stomach time to empty. Loose nightclothes help more than they sound like they should.

Food triggers are individual. Fatty or fried meals, chocolate, mint, coffee, carbonated drinks, citrus and tomato are common culprits, but none is universally harmful, and no diet has been shown to reverse Barrett’s lining. Notice your own triggers and trim them rather than adopting a blanket ban that makes eating joyless.

Three things not to do are less about food. Do not stop or change acid suppression without talking to the prescriber. Do not let a surveillance appointment lapse because you feel well; Barrett’s produces no symptoms, and feeling fine tells you nothing about the biopsies. And do not treat new difficulty swallowing as something to wait out.

What people often get wrong about Barrett's esophagus

“Precancerous means I am going to get cancer.” It means the risk is higher than in someone without Barrett’s, not that cancer is expected. Most people with Barrett’s never develop esophageal cancer, and the annual risk without dysplasia is a fraction of 1 percent according to the NIDDK.

“I never had heartburn, so this cannot be Barrett’s.” Barrett’s itself is silent, and a notable share of people diagnosed have had few or no reflux symptoms. Some reflux is simply not felt.

“The PPI will make it go away.” Acid suppression heals inflammation and may slow progression, but it does not turn columnar cells back into squamous ones. Only removal or ablation of the lining does that, and only when dysplasia justifies it.

“Surgery for reflux fixes Barrett’s.” Fundoplication controls reflux and can free people from daily medicine, but the Mayo Clinic is explicit that it has not been shown to reverse Barrett’s or to remove the need for surveillance.

“A supplement or alkaline diet can reverse it.” No dietary pattern, herb or supplement has been shown to reverse intestinal metaplasia in humans. Claims to the contrary are marketing, not evidence.

“Once ablated, I am done with scopes.” Barrett’s can recur after successful ablation, occasionally beneath the new lining, so surveillance continues for years afterward.

“Barrett’s is causing my symptoms.” Heartburn and regurgitation come from reflux; Barrett’s is the consequence, not the cause. New difficulty swallowing is never explained by Barrett’s itself and needs assessment.

“A longer segment means I already have cancer.” Length raises the odds of progression and shortens the surveillance interval, but it is not a diagnosis. Only biopsies grade the tissue, and only a pathologist reads them.

Questions to ask your care team

The consultation after a Barrett’s diagnosis tends to be short and dense. Writing your questions down beforehand turns the conversation from a lecture into a plan. These are the ones experienced patients say they wished they had asked at the start.

• What grade did the pathologist assign, and if any dysplasia was reported, has a second gastrointestinal pathologist confirmed it?
• How long is my Barrett’s segment, and does it circle the esophagus or run in tongues?
• Given that grade and length, what surveillance interval are you recommending, and what would change it?
• Were my biopsies taken according to a set protocol, and does your unit use high-definition imaging?
• What is the acid-suppression plan, how long will I stay on it, and what should I do if I get breakthrough heartburn?
• If ablation is being suggested, why now rather than another round of surveillance, and what would you expect the course to involve?
• What are the specific risks of the procedure in my case, and how would a stricture be handled if one developed?
• Would a visible nodule be removed by EMR first, and who reviews that tissue?
• After treatment, how often would I be scoped, and for how long?
• Which symptoms should prompt me to call before my next appointment?
• Do my other health conditions affect whether surveillance or treatment makes sense for me?
• Should my first-degree relatives be aware of this diagnosis?

Bring the pathology report, the endoscopy report and a list of every medicine you take, including over-the-counter antacids and supplements. Ask for the plan in writing. A good team will not be put off by the questions; they tend to welcome a patient who knows what the grade on the report means and why the interval was chosen.

When to call your doctor

Barrett’s esophagus itself stays quiet, so the signals that matter are the ones that break the pattern. Contact your care team promptly, or seek urgent care, if any of the following appear:

• Food sticking, or a sense that swallowing has become harder, especially if it is progressive or affects solids more than liquids.
• Painful swallowing that persists beyond the expected few days after a procedure, or begins without one.
• Vomiting blood, or material that looks like coffee grounds.
• Black, tarry stools, which can signal bleeding higher in the gut.
• Unintended weight loss, or loss of appetite that lasts more than a few weeks.
• Persistent chest pain, particularly with breathlessness, sweating or pain spreading to the arm or jaw, which needs emergency assessment as a possible heart problem before it is attributed to reflux.
• After ablation or EMR: fever, severe or worsening chest pain, pain on breathing, or a swollen, tense neck, which can indicate perforation and warrants emergency care.
• Heartburn that returns despite taking acid suppression as prescribed, or hoarseness and chronic cough that will not settle.

None of these confirms cancer or a complication; most turn out to have a simpler explanation. They do mean a phone call rather than a wait for the next scheduled scope. Tell the person you speak to that you have Barrett’s esophagus, because that single fact moves difficulty swallowing from a routine complaint to one that gets an endoscopy quickly.

Routine matters, too. If a surveillance letter does not arrive when expected, chase it. Systems miss people, and the most common failure in Barrett’s care is not the wrong treatment but a scope that quietly never happens. What is done about any of these signs, and how quickly, remains the judgment of the team looking after you.

Frequently asked questions

How to sleep with Barrett's esophagus?

Raise the head of the bed by 6 to 8 inches using blocks or a mattress wedge, a measure the Mayo Clinic recommends for reflux, rather than piling pillows, which bends the neck without tilting the torso. Lying on your left side reduces nighttime acid episodes compared with the right. Finish eating about three hours before bed and wear loose nightclothes. If nighttime heartburn persists despite this, tell your prescriber rather than adjusting medicine yourself.

What is the life expectancy of someone with Barrett's esophagus?

For most people it is similar to that of comparable adults without the condition. Long-term studies consistently find that people with Barrett’s most often die of unrelated causes, particularly heart disease, and that the small yearly cancer risk translates into a modest effect on overall survival. Staying in surveillance, not smoking, and managing weight and reflux are the factors within reach. Individual outlook depends on grade, other health conditions and follow-up, which your team can discuss.

What should you not do with Barrett's esophagus?

Do not smoke, since smoking is the habit most clearly linked to progression. Do not lie down soon after large meals, drink alcohol heavily or ignore central weight gain, all of which worsen reflux. Do not stop or change acid suppression without speaking to the prescriber. Do not skip surveillance because you feel well, because Barrett’s causes no symptoms. And do not wait out new difficulty swallowing; that needs prompt assessment.

How fast does Barrett's esophagus progress to cancer?

Slowly, and in most people not at all. The NIDDK cites a risk of about 0.5 percent per year or lower for Barrett’s without dysplasia, meaning that of 200 people followed for a year, roughly one or fewer would develop cancer. Confirmed low-grade dysplasia raises that risk, and high-grade dysplasia raises it substantially, which is why those grades shift the plan from watching to endoscopic treatment. Long segments, smoking and obesity nudge risk upward.

Can Barrett's esophagus go away or be reversed?

Not with medicine, diet or supplements. Proton pump inhibitors heal inflammation and reduce acid exposure but do not convert the columnar lining back to squamous cells, and no dietary pattern has been shown to reverse intestinal metaplasia in humans. The only way the lining is removed is endoscopic therapy such as radiofrequency ablation or mucosal resection, which guidelines reserve for confirmed dysplasia or very early cancer because of the procedures’ own risks.

Is radiofrequency ablation for Barrett's esophagus painful?

The procedure itself is done under sedation, so people are unaware of it. Afterward, a sore throat and chest discomfort or burning behind the breastbone are common, typically peaking in the first day or two and easing over about a week according to the Mayo Clinic. Swallowing may feel tender, so soft foods are advised for a short period. Pain relief and acid suppression are prescribed by the team, and severe or worsening pain should be reported promptly.

How often do I need an endoscopy for Barrett's esophagus?

It depends on the most recent biopsy grade. With no dysplasia, guidance summarized by the Mayo Clinic and NIDDK suggests roughly every 3 to 5 years, often sooner for long segments. Indefinite results are repeated after a few months of optimized acid suppression. Confirmed low-grade dysplasia is rechecked in 6 to 12 months or treated. After ablation, scopes are more frequent at first and then spaced out. Your gastroenterologist sets the exact interval.

Do I have to take a proton pump inhibitor forever with Barrett's esophagus?

Many people with Barrett’s remain on acid suppression long term because ongoing reflux keeps inflaming the lining, but the duration and intensity are decided by the prescriber based on symptoms, healing and other health factors. PPIs do not reverse Barrett’s, so they are used for control rather than as a stand-alone cancer prevention strategy. Stopping abruptly can cause rebound acid, so any change should be planned with the clinician rather than made on your own.

Does Barrett's esophagus always need treatment?

Everyone with Barrett’s is advised to control reflux and stay in surveillance, but most people never need a procedure. Ablation is not recommended for Barrett’s without dysplasia because the yearly cancer risk is low and the procedure carries its own risks without ending surveillance. Endoscopic therapy is offered for confirmed high-grade dysplasia, early cancer confined to the surface, and some cases of confirmed low-grade dysplasia after a shared discussion with the treating team.

Can Barrett's esophagus come back after ablation?

Yes. After the lining has been cleared, Barrett’s tissue can regrow, sometimes as small islands and occasionally beneath the new squamous surface where it is harder to see. That is why surveillance continues for years after successful treatment, initially more frequently and then at lengthening intervals, and why continued acid suppression through and after healing is usually advised. Recurrent areas found at follow-up can often be treated again endoscopically.

References

• NIDDK (NIH): Barrett's Esophagus
• Cleveland Clinic: Barrett's Esophagus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.